These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

69 related items for PubMed ID: 24053150

  • 21. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
    Miller K, Moul JW, Gleave M, Fizazi K, Nelson JB, Morris T, Nathan FE, McIntosh S, Pemberton K, Higano CS.
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):187-92. PubMed ID: 23381694
    [Abstract] [Full Text] [Related]

  • 22. Immunotherapy in prostate cancer: challenges and opportunities.
    Noguchi M, Koga N, Moriya F, Itoh K.
    Immunotherapy; 2016 Jun; 8(1):69-77. PubMed ID: 26642100
    [Abstract] [Full Text] [Related]

  • 23. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
    Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, Ferro M, Altieri V, Perdonà S, De Placido S, Di Lorenzo G.
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1455-61. PubMed ID: 21365219
    [Abstract] [Full Text] [Related]

  • 24. Emerging therapies in castration resistant prostate cancer.
    Thoreson GR, Gayed BA, Chung PH, Raj GV.
    Can J Urol; 2014 Apr; 21(2 Supp 1):98-105. PubMed ID: 24775731
    [Abstract] [Full Text] [Related]

  • 25. Satraplatin for the therapy of castration-resistant prostate cancer.
    Sonpavde G, Sternberg CN.
    Future Oncol; 2009 Sep; 5(7):931-40. PubMed ID: 19792961
    [Abstract] [Full Text] [Related]

  • 26. Castration-resistant prostate cancer: AUA Guideline.
    Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS.
    J Urol; 2013 Aug; 190(2):429-38. PubMed ID: 23665272
    [Abstract] [Full Text] [Related]

  • 27. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D, De Bono JS.
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [Abstract] [Full Text] [Related]

  • 28. Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.
    Parente P, Parnis F, Gurney H.
    Asia Pac J Clin Oncol; 2012 Mar; 8(1):31-42. PubMed ID: 22369442
    [Abstract] [Full Text] [Related]

  • 29. Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study.
    Gerritse FL, Meulenbeld HJ, Roodhart JM, van der Velden AM, Blaisse RJ, Smilde TJ, Erjavec Z, de Wit R, Los M, NePro Study Investigators.
    Eur J Cancer; 2013 Oct; 49(15):3176-83. PubMed ID: 23849828
    [Abstract] [Full Text] [Related]

  • 30. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
    Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ.
    J Urol; 2007 Dec; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
    [Abstract] [Full Text] [Related]

  • 31. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ, van Werkhoven ED, Coenen JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Fosså SD, Polee M, Gerritsen W, Dalesio O, de Wit R.
    Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
    [Abstract] [Full Text] [Related]

  • 32. [Antisense oligodeoxynucleotide therapy for castration-resistant prostate cancer].
    Miyake H, Fujisawa M.
    Nihon Rinsho; 2014 Dec; 72(12):2121-5. PubMed ID: 25518344
    [Abstract] [Full Text] [Related]

  • 33. Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: a review.
    Colloca G.
    Cancer Treat Rev; 2012 Dec; 38(8):1020-6. PubMed ID: 22503300
    [Abstract] [Full Text] [Related]

  • 34. [New progress of castration-resistant prostate cancer immunotherapy].
    Liu JP, Wang H.
    Zhonghua Wai Ke Za Zhi; 2016 Oct 01; 54(10):787-791. PubMed ID: 27686644
    [Abstract] [Full Text] [Related]

  • 35. Molecular landscape of prostate cancer: implications for current clinical trials.
    Khemlina G, Ikeda S, Kurzrock R.
    Cancer Treat Rev; 2015 Nov 01; 41(9):761-6. PubMed ID: 26210103
    [Abstract] [Full Text] [Related]

  • 36. The success rate of new drug development in clinical trials: Crohn's disease.
    Parker JL, Clare Kohler J.
    J Pharm Pharm Sci; 2010 Nov 01; 13(2):191-7. PubMed ID: 20816005
    [Abstract] [Full Text] [Related]

  • 37. Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer.
    Tsao CK, Galsky MD, Oh WK.
    Eur Urol; 2014 Aug 01; 66(2):184-5. PubMed ID: 24433812
    [Abstract] [Full Text] [Related]

  • 38. Reducing clinical trial risk in multiple sclerosis.
    De Gasperis-Brigante CD, Parker JL, O'Connor PW, Bruno TR.
    Mult Scler Relat Disord; 2016 Jan 01; 5():81-8. PubMed ID: 26856949
    [Abstract] [Full Text] [Related]

  • 39. Sequential therapies in castration-resistant prostate cancer.
    Buonerba C, Di Lorenzo G.
    Future Oncol; 2014 Feb 01; 10(2):153-5. PubMed ID: 24490599
    [No Abstract] [Full Text] [Related]

  • 40. [Treatment of castration-resistant prostate cancer: Evidence-based clinical practice].
    Wang W, Peng RX, Shi GW, Chen SY, Ding Q, He JY.
    Zhonghua Nan Ke Xue; 2015 Dec 01; 21(12):1121-4. PubMed ID: 26817307
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.